At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PK Park Hotels & Resorts Inc.
Closed Christmas Day 12-24 13:00:00 EST
10.87
+0.18
+1.68%
盘后10.94
+0.07+0.64%
16:48 EST
High10.87Low10.68Vol1.61M
Open10.68D1 Closing10.69Amplitude1.78%
Mkt Cap2.17BTradable Cap2.13BTotal Shares199.90M
T/O17.49MT/O Rate0.83%Tradable Shares195.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
GlobeNewswire  ·  12-24 08:45
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
Assessing Park Hotels & Resorts (PK) Valuation After Recent Share Price Underperformance
Simply Wall St.  ·  12-23 22:18
Assessing Park Hotels & Resorts (PK) Valuation After Recent Share Price Underperformance
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
GlobeNewswire  ·  12-17
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire  ·  12-11
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Park Hotels & Resorts to Sell Three More Non-Core Properties, Reaffirms 2025 Outlook
MT Newswires Live  ·  12-09
Park Hotels & Resorts to Sell Three More Non-Core Properties, Reaffirms 2025 Outlook
BRIEF-Park Hotels & Resorts Announces The Sale Of Additional Non-Core Hotels
Reuters  ·  12-09
BRIEF-Park Hotels & Resorts Announces The Sale Of Additional Non-Core Hotels
Park Hotels & Resorts Sells Five Non-Core Hotels for $198 Million
Reuters  ·  12-09
Park Hotels & Resorts Sells Five Non-Core Hotels for $198 Million
Park Hotels & Resorts Inc: Reaffirms FY 2025 Outlook With Oct and Prelim Nov Comparable Revpar Results Largely in Line With Expectations
THOMSON REUTERS  ·  12-09
Park Hotels & Resorts Inc: Reaffirms FY 2025 Outlook With Oct and Prelim Nov Comparable Revpar Results Largely in Line With Expectations
Park Hotels & Resorts Announces the Sale of Additional Non-Core Hotels and Provides Update on Non-Core Hotel Disposition Activity and Recent Operating Trends
THOMSON REUTERS  ·  12-09
Park Hotels & Resorts Announces the Sale of Additional Non-Core Hotels and Provides Update on Non-Core Hotel Disposition Activity and Recent Operating Trends
Three Leading Jiangsu City Commercial Banks Compared: Bank of Jiangsu Leads in Profit, Bank of Nanjing in Revenue Growth, Bank of Suzhou in Risk Control
Deep News  ·  12-05
Three Leading Jiangsu City Commercial Banks Compared: Bank of Jiangsu Leads in Profit, Bank of Nanjing in Revenue Growth, Bank of Suzhou in Risk Control
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
GlobeNewswire  ·  12-04
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
GlobeNewswire  ·  12-04
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
Truist Raises Price Target on Park Hotels & Resorts to $12 From $11, Keeps Hold Rating
MT Newswires Live  ·  12-04
Truist Raises Price Target on Park Hotels & Resorts to $12 From $11, Keeps Hold Rating
Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Dow Jones  ·  12-02
Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
prnewswire  ·  12-02
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo
Dow Jones  ·  12-01
Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire  ·  12-01
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Akebia Announces Establishment of Rare Kidney Disease Pipeline
GlobeNewswire  ·  12-01
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
GlobeNewswire  ·  11-28
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Alphabet vs NVIDIA Ignites Optical Module Sector: Is This the First Step in Rebuilding A-Share Tech Consensus?
Deep News  ·  11-27
Alphabet vs NVIDIA Ignites Optical Module Sector: Is This the First Step in Rebuilding A-Share Tech Consensus?

Introduction

Company Name.
Park Hotels & Resorts Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Park is one of the largest publicly-traded lodging REITs with a diverse portfolio of iconic and market-leading hotels and resorts with significant underlying real estate value. Park's portfolio currently consists of 46 premium-branded hotels and resorts with over 29,000 rooms primarily located in prime city center and resort locations.
Issue price:
--